filmov
tv
Valneva's COVID-19 Vaccine Candidate: An Inside Look at Fill-and-Finish Operations in Sweden
Показать описание
Valneva
Valneva
COVID-19
vaccine
manufacturing
Рекомендации по теме
0:00:12
Susanna M. on her role in inspecting and packaging Valneva's COVID-19 vaccine candidate in Swed...
0:00:54
Valneva agreed with European Commission to Supply up to 60 Million Doses of COVID-19 Vaccine
0:00:53
VALN Valneva SE Announces an Effective COVID-19 Vaccine! Stock Surges on News! 🚀👌🏾👽🙏🏿🕺🏿🇺🇸...
0:01:19
Muscab Salad, Valneva Covid-19 vaccine study participant
0:05:20
Covid-19 vaccine: Is French medical research failing?
1:00:35
Developing new vaccines to protect against infectious diseases at home and abroad
0:01:36
CEO Thomas Lingelbach comments on Valneva's 2020 achievements and focus for 2021
0:02:01
New Novavax vaccine found effective against COVID-19 mutant strains with 60m doses for UK
0:01:16
Visit to Valneva
0:01:15
Valneva Stands with Science
0:07:07
Francks Grimaud (Valneva): Valneva lance la production de son vaccin anti-Covid-19
0:04:35
Valneva : un vaccin avec moins d'effets secondaires
0:20:39
EMA press briefing 18 January 2022
0:10:15
Franck Grimaud (Valneva): Valneva dans la course au vaccin contre le Covid-19
0:04:11
Vaccination : le laboratoire Valneva prévoit un vaccin pour l’automne
0:04:15
Covid : qui est Valneva, la biotech française qui développe un vaccin ? - Reportage 02.02.2021
0:03:02
Mickaël Quiroga : 'Le vaccin français Valneva n’arrivera pas avant 2022… c’est Valnever'...
0:12:49
How Clover Biopharmaceuticals and Dynavax Covid19 Vaccine is Made
0:00:41
WHO hopes COVID-19 vaccination 'underway in every country in next 100 days'
0:02:34
Covid-19 en Europe : bientôt un cinquième vaccin ?
0:51:09
LIVE: Experts hold a briefing on COVID-19 vaccine during the Union World Conference
1:30:55
WS 07 - Novel Vaccine Platforms for Emerging Pandemics and Existing Epidemics
1:04:36
Development of a simian adenovirus vector as a COVID-19 vaccine:progress and perspectives
0:00:43
SK Bioscience releases results from phases 1 and 2 of COVID-19 trial with 99% forming antibodies